Daigaku Nakamura, Takeshi Yanagita, Yoshiaki Fujii, Kaori Watanabe, Takuya Suzuki, Hajime Ushigome, Ruriko Nishigaki, Naomi Sugimura, Mamoru Tanaka, Ryo Ogawa, Hiroki Takahashi, Takaya Shimura, Yuji Hotta, Yoichi Matsuo, Masahiro Kondo, Yoko Furukawa-Hibi, Shuji Takiguchi
BACKGROUND: The standard treatment for colorectal cancer consists of surgery and chemotherapy, which can be combined to improve outcomes. Immune checkpoint inhibitors (ICI) are a significant advancement in the standard treatment of metastatic, unresectable colorectal cancer with deficient mismatch repair (dMMR). However, limited data are available about the use of ICI in the neoadjuvant and conversion settings. Here, we present two cases treated with ICI. CASE PRESENTATION: Case 1: A 75-year-old male with a large, borderline resectable rectal cancer diagnosed as cT4bN1bM0 who underwent neoadjuvant chemotherapy, followed by combination ICI consisting of ipilimumab and nivolumab...
May 1, 2024: Surgical Case Reports